stockrow
Saturday 7 November 2026
Export RZLT’s income statement to Excel — free account
Rezolute, Inc.
RZLT Healthcare Biotechnology
- EPS
- +23.1%
- Free cash flow
- +40.2%
Quarter to June 2026, against a year earlier
3.85
0.21
+5.77%
Follow RZLT
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(59.23%) | (74.02%) | (81.73%) | (59.04%) | |
| (54.73%) | (67.21%) | (74.01%) | (53.82%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(53.39%) | (67.04%) | (71.23%) | (78.26%) | |
Free Cash Flow per Share |
(0.68) | (0.74) | (0.71) | (0.62) | |
Free Cash Flow |
(70.49) | (77.15) | (73.48) | (64.63) | |
| Other line items | |||||
Cash ROIC |
(23.55%) | (29.57%) | (30.99%) | (31.00%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.91 | 0.92 | 0.90 | 0.83 | |
Depreciation/Fixed assets |
(36.37) | (40.68) | (46.88) | (58.98) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.68) | (0.74) | (0.71) | (0.62) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026